Frazier Life Sciences announced the successful closure of its twelfth venture fund at $1.3 billion, earmarked for early-stage biotechnology startups. The oversubscribed fund boosts its capital base to over $3.6 billion across dedicated venture vehicles since 2016, underpinning continued involvement in company creation and drug development. Frazier's portfolio spans oncology and emerging therapeutic areas, highlighting investments in startups like Alentis Therapeutics and Tubulis. While biotech investment faces headwinds due to funding cuts, tariffs, and regulatory uncertainties, Frazier remains bullish on advancing innovative therapies addressing unmet medical needs.